Article Information
History
- April 7, 2020.
Article Versions
- You are currently viewing Version 1 of this article (April 7, 2020 - 06:06).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Antonio Gonçalves1,
- Julie Bertrand1,
- Ruian Ke2,
- Emmanuelle Comets1,
- Xavier de Lamballerie3,
- Denis Malvy4,5,
- Andrés Pizzorno6,
- Olivier Terrier6,
- Manuel Rosa Calatrava6,
- France Mentré1,
- Patrick Smith7,
- Alan S Perelson2 and
- Jérémie Guedj1,*
- 1Université de Paris, IAME, INSERM, F-75018 Paris, France
- 2Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA
- 3UMR “Emergence des Pathologies Virales” (EPV: Aix-Marseille University - IRD 190 - Inserm 1207 - EHESP) - Institut Hospitalo-Universitaire Méditerranée Infection, F-13385 Marseille, France
- 4Inserm, UMR 1219, Université de Bordeaux, Bordeaux, France
- 5Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
- 6Virologie et Pathologie Humaine - VirPath team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France
- 7Certara, Integrated Drug Development, Princeton, NJ, USA
- ↵*Corresponding author: Jeremie Guedj, jeremie.guedj{at}inserm.fr, 16 rue Henri Huchard, 75018, Paris, France
Posted April 07, 2020.
Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load
